CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Digoxin 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04834557
NCT04834557Phase 2Completed
CompareCT.gov

Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis in Egypt

Tanta University·interventional·Posted Apr 8, 2021·Updated Mar 22, 2023

In Brief

A Phase 2 clinical trial evaluating Placebo, Digoxin 0.25 mg, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the potential therapeutic effects of the cardiac glycoside digoxin and the secondary bile acid ursodeoxycholic acid (UDCA) on synovial inflammation and disease activity when administered as add-on treatments to the current DMARDs treatments for rheumatoid arthritis patients with variant disease activity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesEgypt
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 8, 2021
Enrollment StartNov 1, 2021
Primary CompletionMay 18, 2022
Study CompletionSep 30, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.2 years ago

Interventions

Placebodrug

Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Digoxin 0.25 mgdrug

All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Ursodeoxycholic acid (UDCA) 500 mgdrug

All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.